(B) Extinction of Fear
ConditioningTraining
+ 48 h
Recall of extinction
+ 24 h
Recall session
0 + 3 min
Administration of drug/vehicle
Extinction procedure
+ 10 min
The present study aimed to compare the mnemotropic potency of molecules that have bifunctional activity (a concomitant effect on the NMDA- and AMPA–receptors) against monofunctional drugs: the low-affinity NMDA receptor blocker memantine and the positive AMPA receptor modulator QQX. New bio-isosteric analogues of MK-801 (IPAC 1-5) were synthesized and designed to have bifunctional activity. Low-affinity NMDA blockade was achieved by introducing greater flexibility into the molecule, and AMPA receptor stimulation was produced by introduction of a sulfamide-containing derivative of isothiourea in the structure. Dimebon, a weak antagonist (IC50=10 µM) of NMDA-receptor2 and a positive modulator of AMPA receptors at low concentrations (1-20 µM)3, has revealed memory enhancing properties in in vivo studies2,4 which are suggested to be due to its interaction with other neuromediatory systems and mechanisms in additional to glutamatergic2.
Correspondence to:Dr Tatyana Strekalova
[email protected]/mhens
School for Mental Health and NeuroscienceDiv. Neuroscience
T +3143 388 4110F +3143 367 1096
Maastricht University - address
P.O. Box 6166200 MD Maastricht, The Netherlands
Simultaneous Versus Solitary Pharmacological Manipulation of NMDA- and AMPA-receptors: Effects of New Drugs on Contextual Learning and its Extinction
Vignisse JulieA,B, Steinbusch H.W.M.A, Griegoriev V.C, Bettendorff L.B, Bolkunov A.C, Nunes J.D, Bachurin S.C and Strekalova T.A,D
A Department of Neurosciences, MHeNS, Maastricht University, NetherlandsB Bioenergetics And Cerebral Excitability Unit, GIGA-Neurosciences, University of Liege, Liège, BelgiumC IPAC, Russian Academy of Sciences, Chernogolovka/Moscow , RussiaD Center of Environmental Biology, Faculty of Sciences, Lisbon University, Lisbon, Portugal;
MHeNS, School for Mental Health and Neuroscience
INTRODUCTION
CONCLUSIONS
REFERENCESAKNOWLEDGEMENTS
2) IPAC 5 (0.5 mg/kg) and Memantine (5 mg/kg), but not QQX (5 mg/kg) enhance the acquisition of the step-down avoidance task
IPAC-2-5NH
R2
R3
N
S
NH
R1
R2
R3
N
S
NR
1
R2
R3
R4
R1-N=C=S +HHal
R4Hal
acetone, r.t.Et2O, r.t.(B)
S
O
N
NNH
ClCH3 Cl
NHCH3
CH3
CH3CH3
N
N
N
SNH
CH3
NHCH3
CH3
CH3CH3
NH2
Cl
NHCH3
CH3
CH3CH3
NH
N
N
SNH
CH3 Cl
NHCH3
CH3
CH3CH3
NH
N
N
SNH
CH3
NaBH4
MeOH, 40 50°C
H2O+(A)
IPAC-1
Figure 1 : The synthesis of five tested bio-isosteric analogues of MK-801. (A) Routes of synthesis of IPAC-1; (B) Routes of synthesis of IPAC-2-5 compounds (radicals in the formulas: IPAC-2: R1 = Ph, R2 = Bn, R3 = Me, R4 = Bn, Hal = Br. IPAC-3: R1 = Bn, R2 = H, R3 = H, R4 = 2-Cyclohexenyl, Hal = Br; IPAC-5: R1 = All, R2 = Bn, R3 = H, R4 = Et, Hal = I).
Study design
The effects of new drugs on NMDA receptors were studied on isolated cortical neurons that contained a population of NMDA receptors; NMDA solutions of 1-100 μΜ containing 7 μΜ of glycine were applied to activate the receptor. The effects of tested compounds on the stimulation of AMPA receptors were investigated on isolated Purkinje neurons using partial receptor agonist kainic acid (KA), which induces AMPA-receptor mediated currents while evoking relatively low receptor desensitization. The effects of IPAC 1-3 and 5, dimebon, positive modulator of AMPA receptor QXX and memantine on learning were studied in (A) the step-down avoidance task and in (B) a fear conditioning paradigm. Dimebon has been reported to have pro-cognitive effects in these models2,4 and was used as an independent positive control.
(B) Contextual Freezing Before Dosing
0
20
40
60
80
100
Con Dim IPAC-1 IPAC-2 IPAC-5DMSO Mem 5 IPAC-3QXX 5 QXX 1
Per
cen
t o
f ti
me
spen
tw
ith
fre
ezin
g,
%
Figure 3: Effects of bio-isosteric analogues of MK-801 on extinction of contextual freezing in a fear-conditioning paradigm. (A) During recall of memory extinction trials, the percentage of time spent in freezing was decreased in mice treated with QXX at a dose of 5 mg/kg, with IPAC-5 and with dimebon (versus respective control group, *p<0.05) suggesting that these drugs facilitated fear memory extinction. Groups treated with memantine (5 mg/kg), QXX at a dose of 1 mg/kg, IPAC-1, IPAC-2, and IPAC-3 showed no changes in freezing behaviour during a recall of extinction session. (B) During a recall session of fear conditioning, before dosing, all groups showed similar freezing rates. Each column represents the mean ± SEM. Symbols are as in Figure 2 except for QXX 1 or 5: QQX (1 or 5 mg/kg) - treated group.
(A) Extinction of Contextual Fear Conditioning
0
20
40
60
80
100
Con Dim IPAC-1 IPAC-2 IPAC-5DMSO Mem 5 IPAC-3QXX 5 QXX 1
* **
Per
cen
t o
f ti
me
sp
ent
wit
h f
reez
ing
, s
3) IPAC 5 (0.5 mg/kg) and QXX (5 mg/kg), but not memantine (5 mg/kg) facilitate extinction of contextual memory
BACKGROUND
B 1h 24h B 1h 24h B 1h 24h B 1h 24h B 1h 24h B 1h 24h B 1h 24h B 1h 24h B 1h 24h B 1h 24h
0
50
100
150
200Con Dim IPAC-1 IPAC-2 IPAC-5DMSO IPAC-3QXX 5Mem 5Mem 1
#
***
##
Lat
ency
of
step
do
wn
, s
Figure 2. Effects of bio-isosteric analogues of MK-801 on contextual learning in the step-down avoidance test. Mice treated with memantine at a dose of 5 mg/kg or dimebon or IPAC-5 revealed significant increase in the latency of step down 1 h (*p<0.05) and 24 h after training (#p<0.05) as compared with respective control groups, suggesting that the administration of these drugs enhances both short-term and long-term memories in this task. No such effects were observed in animals treated by memantine at a dose of 1 mg/kg, QXX, IPAC-1, IPAC-2 or IPAC-3. Each column represents the mean ± SEM. Experimental groups: Con: saline-treated control; DMSO: DMSO-treated control; Mem 1 or 5: memantine (1 mg/kg or 5 mg/kg); Dim: dimebon (1 mg/kg); QXX- (5 mg/kg), IPAC-1- (1 mg/kg), IPAC-2- (0.5 mg/kg), IPAC-3- (1 mg/kg), IPAC-5 (0.5 mg/kg)- treated group.
This study was supported by Internationale Stichting Alzheimer Onderzoek (ISAO) grant N 09501 to T.S. (International Foundation on Alzheimer’s disease research, the Netherlands), by the Royal Netherlands Academy of Arts and Sciences (KNAW) and by the Fonds pour la formation à la Recherche dans l'Industrie et dans l'Agriculture (FRIA) to J.V. Authors are grateful to Dr Alexei Proshin for providing us new compounds used in this study.
1 Gonda, Curr. Pharm Des. 2012;18(12):1558-67. 2 Bachurin & al., Ann N Y Acad Sci. 2001;939:425-35. 3 Grigoriev, Dranyi & Bachurin, Bull Exp Biol Med. 2003;136(5):474-7. 4 Vignisse & al., Prog Neuropsychopharmacol Biol Psychiatry 2011;35(2):510-22.
(A) Step-down Avoidance
+ 15 min
Training
+ 24 h+ 1 h
Recall session 1
Recall session 2
Administration of drug or vehicle
0
RESULTS
Table 1 : Magnitudes of electrophysiological mono- and bi-functional effects of QXX, Memantine and new bio-isoteric analogs of MK-801 (IPAC 1-5) on AMPA- and NMDA-receptors. Freshly isolated neurons from 9-16-day-old rat pups were used for the patch-clamp technique. NMDA-receptor mediated currents were studied in cortical slices. AMPA-receptor mediated currents were studied in Purkinje neurons of the cerebellum3. Arrows indicate the effects of drugs on NMDA- and AMPA-receptors: „high‟ (↓↓) or „moderate‟ (↓) blockade and „high‟ (↑↑) or „moderate‟ (↑) positive modulation.
1) IPAC 5 was used as a drug of superior concomitant effects on both NMDA and AMPA receptors
o A concomitant low affinity NMDA receptor blockade and AMPA stimulation enhance memory
o Mono-drugs replicate the properties of bifunctional drugs at ten-fold higher doses
o Multi-target memory enhancers have a high potential for clinical implications
The development of novel memory enhancers for treating cognitive deficits associated with neurological and psychiatric disorders remains a primary focus of study in central nervous system research. Glutamatergic system has been identified as a central element in this purpose. Indeed, low-affinity blockade of NMDA-receptors or potentiation of AMPA-receptors have been reported to result in memory enhancement but the administration of many of them presents problems with their side-effects1. Therefore, developping molecules that combine procognitive effects of NMDA low-affinity receptor blocker and AMPA positive modulator while decreasing their adverse effects is of the most importance. Bifunctional drug therapy targeting distinct receptor signalling systems can generate increased efficacy at lower concentrations compared to monofunctional therapy.
1050%30 µM
1.0 – 30 µM
148 %0.5 µM
0.02 - 1.0 µM
150 %0.5 µM
0.5 – 1.0 µM
230%0.01-0.1 µM
0.001– 1.0 µM
210%0.001 µM
1.10-5-0.01 µM
n.a.
Potentiation of AMPA-R in % from control, dose of maximal effects
and range of effective doses
0.4±0.07and
21.2±2.150.8±0.113.2±0.4721.4±1.58n.a. 1.2±0.15Blockade of NMDA–R: IC50 (µM)
High ↓↓
High ↑↑
High ↓↓
Mod ↑
Mod ↓
Mod ↑
Mod ↓
High ↑↑High ↑↑
High ↓↓
Potency to affect NMDA and/or AMPA receptors
Non competitive blockade of NMDA-R
Potentiation of AMPA-R
IPAC-5IPAC-3IPAC-2IPAC-1MemantineQQX
1050%30 µM
1.0 – 30 µM
148 %0.5 µM
0.02 - 1.0 µM
150 %0.5 µM
0.5 – 1.0 µM
230%0.01-0.1 µM
0.001– 1.0 µM
210%0.001 µM
1.10-5-0.01 µM
n.a.
Potentiation of AMPA-R in % from control, dose of maximal effects
and range of effective doses
0.4±0.07and
21.2±2.150.8±0.113.2±0.4721.4±1.58n.a. 1.2±0.15Blockade of NMDA–R: IC50 (µM)
High ↓↓
High ↑↑
High ↓↓
Mod ↑
Mod ↓
Mod ↑
Mod ↓
High ↑↑High ↑↑
High ↓↓
Potency to affect NMDA and/or AMPA receptors
Non competitive blockade of NMDA-R
Potentiation of AMPA-R
IPAC-5IPAC-3IPAC-2IPAC-1MemantineQQX